Par Pharmaceutical wins in Ultram ER litigation

Par Pharmaceutical Companies, Inc. today announced that the U.S. District Court for the District of Delaware has ruled in favor of Par in its challenge of Purdue's patents relating to extended-release tramadol, which are listed in the Orange Book for Ortho-McNeil's Ultram(R) ER product.

Par earlier announced that it had filed an ANDA seeking marketing approval for generic extended-release tramadol, and that it was the first-filed ANDA with respect to the Ultram ER product.

Par currently has tentative approval on two of the three strengths (100mg and 200mg) of tramadol ER. Par intends to review its options with respect to its tramadol ER ANDA.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Biosynth’s unique online custom peptide toolset completed with full order tracking and QC data portal